RESUMEN
Idiopathic granulomatous mastitis (IGM) is a benign chronic inflammatory breast disease of unknown etiology. No consensus exists as to the best therapeutic approach, though treatment choices include antibiotics, drainage, surgical excision, steroids, methotrexate, and observation. Herein we report a case of idiopathic granulomatous mastitis that was refractory to methotrexate and intralesional and systemic steroids but responded well to mycophenolate mofetil 1500mg twice daily. To our knowledge, this is the first report of the effective use of mycophenolate mofetil in idiopathic granulomatous mastitis.
Asunto(s)
Inhibidores Enzimáticos/uso terapéutico , Mastitis Granulomatosa/tratamiento farmacológico , Ácido Micofenólico/uso terapéutico , Adulto , Diagnóstico Diferencial , Femenino , Mastitis Granulomatosa/patología , HumanosAsunto(s)
COVID-19/complicaciones , Tiempo de Internación/estadística & datos numéricos , Úlcera por Presión/epidemiología , Púrpura/sangre , Centros Médicos Académicos , Adulto , Anciano , Femenino , Hospitales Urbanos , Humanos , Incidencia , Intubación Intratraqueal/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Úlcera por Presión/sangre , Úlcera por Presión/etiología , Posición Prona , Púrpura/virología , Estudios Retrospectivos , SARS-CoV-2RESUMEN
INTRODUCTION: Little is known about emergency department (ED) utilization for herpes simplex viruses (HSV) types 1 and 2 in the United States. Our goal was to determine the utilization and cost burden associated with HSV infection visits to U.S. EDs in recent years from 2006-2013. METHODS: We analyzed the Nationwide Emergency Department Sample (NEDS) database, the largest national database of hospital-based ED visits in the U.S., to determine the number of visits and the cost associated with HSV visits from 2006-2013. We also analyzed trends across years. RESULTS: From 2006-2013, there were 704,728 ED visits with a primary diagnosis of HSV infection. Of these, 658,805 (93.5%) resulted in routine discharges without inpatient admission, amounting to a total ED charge of $543.0 million. After adjusting for inflation, there was a doubling of total ED spending for HSV from 2006 to 2013 ($45.0 million to $90.7 million) and a 24% increase in number of visits (73,227 visits in 2006, vs. 90,627 visits in 2013). ED visits for genital herpes have increased while visits for herpes gingivostomatitis have decreased. CONCLUSION: HSV-associated ED use and associated costs have increased between 2006-2013. Most of these cases could likely be managed in non-emergent outpatient settings as 93.5% of visits resulted in routine discharges without admission. Our findings add to knowledge regarding HSV utilization and epidemiology in the U.S. and highlight the need for continued prevention, patient education, and emphasis of care in non-emergency settings to prevent unnecessary ED utilization.